These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 21700346)

  • 1. Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia.
    Lodge DJ; Grace AA
    Trends Pharmacol Sci; 2011 Sep; 32(9):507-13. PubMed ID: 21700346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel α5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia.
    Gill KM; Lodge DJ; Cook JM; Aras S; Grace AA
    Neuropsychopharmacology; 2011 Aug; 36(9):1903-11. PubMed ID: 21562483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways.
    Perez SM; Lodge DJ
    Drug Des Devel Ther; 2014; 8():887-96. PubMed ID: 25061280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia.
    Grace AA
    Neuropharmacology; 2012 Mar; 62(3):1342-8. PubMed ID: 21621548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive Allosteric Modulation of α5-GABAA Receptors Reverses Stress-Induced Alterations in Dopamine System Function and Prepulse Inhibition of Startle.
    McCoy AM; Prevot TD; Mian MY; Cook JM; Frazer A; Sibille EL; Carreno FR; Lodge DJ
    Int J Neuropsychopharmacol; 2022 Aug; 25(8):688-698. PubMed ID: 35732272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging therapeutic targets for schizophrenia: a framework for novel treatment strategies for psychosis.
    Sonnenschein SF; Grace A
    Expert Opin Ther Targets; 2021 Jan; 25(1):15-26. PubMed ID: 33170748
    [No Abstract]   [Full Text] [Related]  

  • 7. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.
    Howes OD; Egerton A; Allan V; McGuire P; Stokes P; Kapur S
    Curr Pharm Des; 2009; 15(22):2550-9. PubMed ID: 19689327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vagal nerve stimulation reverses aberrant dopamine system function in the methylazoxymethanol acetate rodent model of schizophrenia.
    Perez SM; Carreno FR; Frazer A; Lodge DJ
    J Neurosci; 2014 Jul; 34(28):9261-7. PubMed ID: 25009259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia.
    Lodge DJ; Grace AA
    J Neurosci; 2007 Oct; 27(42):11424-30. PubMed ID: 17942737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developmental pathology, dopamine, stress and schizophrenia.
    Lodge DJ; Grace AA
    Int J Dev Neurosci; 2011 May; 29(3):207-13. PubMed ID: 20727962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant dopamine D2-like receptor function in a rodent model of schizophrenia.
    Perez SM; Lodge DJ
    J Pharmacol Exp Ther; 2012 Nov; 343(2):288-95. PubMed ID: 22859862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hippocampal α5-GABA
    Perez SM; McCoy AM; Prevot TD; Mian MY; Carreno FR; Frazer A; Cook JM; Sibille E; Lodge DJ
    Biol Psychiatry Glob Open Sci; 2023 Jan; 3(1):78-86. PubMed ID: 36712569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia.
    Lodge DJ; Grace AA
    Neurotox Res; 2008 Oct; 14(2-3):97-104. PubMed ID: 19073417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hippocampal deep brain stimulation reverses physiological and behavioural deficits in a rodent model of schizophrenia.
    Perez SM; Shah A; Asher A; Lodge DJ
    Int J Neuropsychopharmacol; 2013 Jul; 16(6):1331-9. PubMed ID: 23190686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BL-1020, an oral antipsychotic agent that reduces dopamine activity and enhances GABAA activity, for the treatment of schizophrenia.
    Fitzgerald PB
    Curr Opin Investig Drugs; 2010 Jan; 11(1):92-100. PubMed ID: 20047163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3-Aminomethyl Derivatives of 2-Phenylimidazo[1,2-a]-pyridine as Positive Allosteric Modulators of GABA
    Marcinkowska M; Kołaczkowski M; Kamiński K; Bucki A; Pawłowski M; Siwek A; Karcz T; Starowicz G; Słoczyńska K; Pękala E; Wesołowska A; Samochowiec J; Mierzejewski P; Bienkowski P
    ACS Chem Neurosci; 2017 Jun; 8(6):1291-1298. PubMed ID: 28211669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of dopamine D(2) receptors for antipsychotic activity.
    Ginovart N; Kapur S
    Handb Exp Pharmacol; 2012; (212):27-52. PubMed ID: 23129327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into the Mechanism of Action of Antipsychotic Drugs Derived from Animal Models: Standard of Care versus Novel Targets.
    Grace AA; Uliana DL
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deletion of dopamine D
    Tomasella E; Bechelli L; Ogando MB; Mininni C; Di Guilmi MN; De Fino F; Zanutto S; Elgoyhen AB; Marin-Burgin A; Gelman DM
    Proc Natl Acad Sci U S A; 2018 Mar; 115(13):3476-3481. PubMed ID: 29531031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipsychotic drug-induced increases in ventral tegmental area dopamine neuron population activity via activation of the nucleus accumbens-ventral pallidum pathway.
    Valenti O; Grace AA
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):845-60. PubMed ID: 19751544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.